Αποτελέσματα Αναζήτησης
13 Απρ 2023 · Treatment of community-acquired pneumonia in adults in the outpatient setting; Treatment of hospital-acquired and ventilator-associated pneumonia in adults; Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults
5 Απρ 2024 · Selection of the initial regimen depends on the adverse effect profiles of available agents, potential drug interactions, patient allergies, and other patient-specific factors.
19 Ιουν 2024 · Hospital-acquired (or nosocomial) pneumonia (HAP) is an important cause of morbidity and mortality despite improved prevention, antimicrobial therapy, and supportive care . The treatment of non-ventilator-associated HAP (nvHAP) and ventilator-associated pneumonia (VAP) will be reviewed here.
1 Οκτ 2019 · Side effects of corticosteroids (on the order of 240 mg of hydrocortisone per day) include significant increases in hyperglycemia requiring therapy and possible higher secondary infection rates (178, 179). No reported study has shown excess mortality in the corticosteroid-treated group.
The major limitation of CURB-65 and CRB-65 is the exclusion of comorbidities that may increase the risk of complications in CAP, such as alcoholism, heart or liver failure, and neoplasia, which results in their negative predictive value for mortality being slightly lower than that of the PSI. 5, 40 However, CURB-65 and CRB-65 are qualified by their simplicity, immediate applicability, and ease ...
14 Αυγ 2018 · Key points. •. Pneumonia is a common respiratory infection and warrants careful consideration of antibiotic initiation and choice, along with knowledge of local antibiotic resistance patterns. •. Community-acquired pneumonia afflicts all age groups and although not always bacterial in origin, is clinically versatile, depending on its cause. •.
2 Απρ 2015 · The choice of empirical antibiotic treatment for patients with clinically suspected community-acquired pneumonia (CAP) who are admitted to non–intensive care unit (ICU) hospital wards is...
